Nkarta (NKTX) Change in Accured Expenses (2019 - 2026)
Nkarta's quarterly Change in Accured Expenses came in at -$3.9 million in Q1 2026, down 2117.71% year-on-year from $192000.0 in Q1 2025, and down 253.37% quarter-over-quarter from $2.5 million in Q4 2025.
Nkarta has reported Change in Accured Expenses for 8 years, with the latest figure at -$3.9 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 2117.71% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$1.6 million (down 29.9% YoY), and the FY2025 full-year result was $2.5 million, up 155.11% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$3.9 million, down from $2.5 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $4.6 million in Q3 2022, with the low at -$3.9 million in Q1 2026.
- Average Change in Accured Expenses over 5 years is $64705.9, with a median of $192000.0 recorded in 2025.
- Year-over-year, Change in Accured Expenses soared 285.08% in 2023 and plunged 2117.71% in 2026.
- Tracing NKTX's Change in Accured Expenses over 5 years: stood at -$619000.0 in 2022, then soared by 196.28% to $596000.0 in 2023, then tumbled by 512.08% to -$2.5 million in 2024, then soared by 202.85% to $2.5 million in 2025, then plunged by 253.37% to -$3.9 million in 2026.
- The last three Change in Accured Expenses figures came in at -$3.9 million (Q1 2026), $2.5 million (Q4 2025), and $448000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.87 Mn |
| Mar 31, 2026 | -3.87 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Jun 30, 2025 | -703,000.00 |
| Jun 30, 2025 | -703,000.00 |
| Mar 31, 2025 | 192,000.00 |
| Mar 31, 2025 | 192,000.00 |
| Dec 31, 2024 | -2.46 Mn |
| Dec 31, 2024 | -2.46 Mn |
| Sep 30, 2024 | 130,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | -3.04 Mn |
| Mar 31, 2024 | -3.04 Mn |
| Dec 31, 2023 | 596,000.00 |
| Dec 31, 2023 | 596,000.00 |
| Sep 30, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 3.41 Mn |
| Jun 30, 2023 | 3.41 Mn |
| Mar 31, 2023 | -1.33 Mn |
| Mar 31, 2023 | -1.33 Mn |
| Dec 31, 2022 | -619,000.00 |
| Dec 31, 2022 | -619,000.00 |
| Sep 30, 2022 | 4.65 Mn |
| Sep 30, 2022 | 4.65 Mn |
| Jun 30, 2022 | 885,000.00 |
| Jun 30, 2022 | 885,000.00 |
| Mar 31, 2022 | -2.16 Mn |
| Mar 31, 2022 | -2.16 Mn |
| Dec 31, 2021 | 861,000.00 |
| Dec 31, 2021 | 861,000.00 |
| Sep 30, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.65 Mn |
| Jun 30, 2021 | 927,000.00 |
| Jun 30, 2021 | 927,000.00 |
| Mar 31, 2021 | -642,000.00 |
| Mar 31, 2021 | -642,000.00 |
| Dec 31, 2020 | 294,000.00 |
| Dec 31, 2020 | 294,000.00 |
| Sep 30, 2020 | 2.55 Mn |
| Sep 30, 2020 | 2.55 Mn |
| Jun 30, 2020 | -453,000.00 |
| Jun 30, 2020 | -453,000.00 |
| Mar 31, 2020 | 426,000.00 |
| Mar 31, 2020 | 426,000.00 |
| Dec 31, 2019 | 1.57 Mn |
| Dec 31, 2019 | 1.57 Mn |
| Sep 30, 2019 | 1.02 Mn |
| Sep 30, 2019 | 1.02 Mn |